NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
64.72%
1 Year Est. Return
+64.72%
AUM
$1.62B
AUM Growth
+$206M
(+15%)
Holding
167
Top Buys
| 1 | +$19.3M | |
| 2 | +$17.2M | |
| 3 | +$14.8M | |
| 4 |
Geron
GERN
|
+$12.4M |
| 5 |
LBRX
LB Pharmaceuticals
LBRX
|
+$10.7M |
Top Sells
| 1 | +$78.6M | |
| 2 | +$61M | |
| 3 | +$27.2M | |
| 4 |
Nektar Therapeutics
NKTR
|
+$16.6M |
| 5 |
THRD
Third Harmonic Bio
THRD
|
+$16M |
Sector Composition
| 1 | Healthcare | 69.32% |
| 2 | Consumer Discretionary | 12.89% |
| 3 | Financials | 5.23% |
| 4 | Communication Services | 4.07% |
| 5 | Industrials | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
enVVeno Medical
NVNO
$6.8M
| – | – |
-594,661
|
|
||
152
Olaplex Holdings
OLPX
$821M
| – | – |
-650,000
|
|
||
153
Children's Place
PLCE
$175M
| – | – |
-57,030
|
|
||
154
Regeneron Pharmaceuticals
REGN
$72.8B
| – | – |
0
|
|
||
155
RH
RH
$2.96B
| – | – |
0
|
|
||
156
Rezolute
RZLT
$913M
| – | – |
-2,291,395
|
|
||
157
Syndax Pharmaceuticals
SNDX
$1.7B
| – | – |
-754,503
|
|
||
158
Transact Technologies
TACT
$45.1M
| – | – |
-15,046
|
|
||
159
Teva Pharmaceuticals
TEVA
$32.8B
| – | – |
0
|
|
||
|
THRD
160
DELISTED
Third Harmonic Bio
THRD
| – | – |
-2,938,700
|
|
||
|
THTX
161
DELISTED
Theratechnologies
THTX
| – | – |
-2,422,563
|
|
||
|
TRML
162
DELISTED
Tourmaline Bio
TRML
| – | – |
-558,187
|
|
||
163
UroGen Pharma
URGN
$1.06B
| – | – |
-6,703
|
|
||
|
VERV
164
DELISTED
Verve Therapeutics
VERV
| – | – |
-331,437
|
|
||
165
Viatris
VTRS
$12.9B
| – | – |
0
|
|
||
166
State Street SPDR S&P Biotech ETF
XBI
$7.55B
| – | – |
0
|
|
||
167
Exagen
XGN
$159M
| – | – |
-61,186
|
|